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Background: Individuals with rheumatoid arthritis (RA) are at increased risk for myocardial infarction and stroke, cardiovascular events attributed 
to heightened systemic inflammation and endothelial dysfunction. B-cells play an important pathogenic role in RA, and Rituximab, a chimeric 
murine/human monoclonal antibody that depletes B-cells, is effective therapy for this disease. The purpose of this study was to determine the 
effects of B-cell depletion on systemic inflammation and endothelial function as assessed by flow-mediated vasodilation (FMD) of the brachial artery 
in patients with RA.
Methods: We studied patients with active RA who had high levels of systemic inflammation with either hsCRP ≥10mg/L or ESR >30mm/h. Patients 
received 1000mg rituximab IV infusion at baseline and on day 15. FMD, inflammatory markers, and clinical assessments were performed at baseline, 
week 12, and week 24.
Results: Of the 20 patients who completed the study , the median age was 54 years and 95% were females. Forty percent had hypertension, 
25% hyperlipidemia, 20% DM and 25% were current smokers. At baseline, the median hsCRP and ESR were 16.6mg/L and 45mm/h respectively. 
The median FMD at baseline was 3.9% (IQR 3.4 to 5.8). At week 12, the FMD improved to 6.1%(IQR 4.9 to 7.6%, p=0.016); by week 24, the 
FMD decreased to 4.4%(IQR 3.3 to 6.1, similar to the baseline FMD, p=1.0). In contrast, both hsCRP and ESR decreased significantly at week 
12 (6.8mg/L, and 30mm/h respectively, p=0.058 and p=0.04 vs baseline) and at week 24 (7.8mg/L and 30mm/h, p=0.008 and p=0.003 vs. 
baseline). Rituximab induced a nearly complete depletion of B-cells for the entire 24-week study period.
Conclusion: B-cell depletion in patients with active RA had a differential impact on endothelial dysfunction and systemic inflammation. The 
improvement in endothelial function was marked (absolute FMD increase 2.2% at 12 weeks) but transient. In contrast, there was sustained 
improvement in systemic inflammation for 24 weeks. Given the clinical importance of excess cardiovascular risk in RA, studies are needed to explore 
the mechanisms by which B-cells contribute to endothelial dysfunction and systemic inflammation in active RA.
